Infectious mononucleosis is associated with an increased incidence of NAFLD.
EBV
NASH
steatohepatitis
virus
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
07
11
2022
received:
04
10
2022
accepted:
13
11
2022
pubmed:
22
11
2022
medline:
15
2
2023
entrez:
21
11
2022
Statut:
ppublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. Although various genetic and lifestyle-related risk factors have been identified, its pathophysiology has not yet been fully unravelled. While acute EBV infection in the setting of infectious mononucleosis can lead to acute hepatitis, the long-term hepatic sequelae of infectious mononucleosis are still poorly understood. This retrospective cohort study included 13,859 patients with and 13,859 matched individuals without infectious mononucleosis from the Disease Analyzer database (IQVIA). Multivariable Cox regression analyses were used to evaluate the association between infectious mononucleosis and NAFLD. Within 10 years of the index date, 2.64% of patients with infectious mononucleosis and 1.78% of individuals without infectious mononucleosis had been diagnosed with NAFLD (p < .001). The incidence of NAFLD was 263.9 cases per 100,000 person-years among individuals with infectious mononucleosis and 164.5 cases per 100,000 person-years among those without. Multivariable regression analyses indicated that infectious mononucleosis was significantly associated with the incidence of NAFLD (HR: 1.73) both among women (HR: 1.73) and among men (HR: 1.70). In age-stratified analyses, the association between infectious mononucleosis and NAFLD was most pronounced for the groups aged between 41 and 50 years (HR: 2.94) and >50 years (HR: 2.68). Infectious mononucleosis is significantly associated with the incidence of NAFLD in a large cohort from Germany. These findings suggest a pathophysiological involvement of EBV in the development of NAFLD and could stimulate research efforts to better understand the pathophysiology of this emerging global medical burden.
Sections du résumé
BACKGROUND
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. Although various genetic and lifestyle-related risk factors have been identified, its pathophysiology has not yet been fully unravelled. While acute EBV infection in the setting of infectious mononucleosis can lead to acute hepatitis, the long-term hepatic sequelae of infectious mononucleosis are still poorly understood.
METHODS
METHODS
This retrospective cohort study included 13,859 patients with and 13,859 matched individuals without infectious mononucleosis from the Disease Analyzer database (IQVIA). Multivariable Cox regression analyses were used to evaluate the association between infectious mononucleosis and NAFLD.
RESULTS
RESULTS
Within 10 years of the index date, 2.64% of patients with infectious mononucleosis and 1.78% of individuals without infectious mononucleosis had been diagnosed with NAFLD (p < .001). The incidence of NAFLD was 263.9 cases per 100,000 person-years among individuals with infectious mononucleosis and 164.5 cases per 100,000 person-years among those without. Multivariable regression analyses indicated that infectious mononucleosis was significantly associated with the incidence of NAFLD (HR: 1.73) both among women (HR: 1.73) and among men (HR: 1.70). In age-stratified analyses, the association between infectious mononucleosis and NAFLD was most pronounced for the groups aged between 41 and 50 years (HR: 2.94) and >50 years (HR: 2.68).
CONCLUSION
CONCLUSIONS
Infectious mononucleosis is significantly associated with the incidence of NAFLD in a large cohort from Germany. These findings suggest a pathophysiological involvement of EBV in the development of NAFLD and could stimulate research efforts to better understand the pathophysiology of this emerging global medical burden.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13911Informations de copyright
© 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399:61-116.
Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398:1359-1376.
Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212-2224.
Huh Y, Cho YJ, Nam GE. Recent epidemiology and risk factors of nonalcoholic fatty liver disease. J Obes Metab Syndr. 2022;31:17-27.
Zelber-Sagi S, Grinshpan LS, Ivancovsky-Wajcman D, Goldenshluger A, Gepner Y. One size does not fit all; practical, personal tailoring of the diet to NAFLD patients. Liver Int. 2022;42:1731-1750. doi:10.1111/liv.15335
Liebe R, Esposito I, Bock HH, et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021;74:1455-1471.
Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: a matter of life and death. Nat Rev Gastroenterol Hepatol. 2018;15:738-752.
Bilson J, Sethi JK, Byrne CD. Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function. Proc Nutr Soc. 2022;81:146-161.
Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1:75-82.
Shen Y, Wang YF. Chronic active Epstein-Barr virus enteritis: a literature review. J Dig Dis. 2022;23:248-252. doi:10.1111/1751-2980.13097
Loosen SH, Doege C, Meuth SG, Luedde T, Kostev K, Roderburg C. Infectious mononucleosis is associated with an increased incidence of multiple sclerosis: results from a cohort study of 32,116 outpatients in Germany. Front Immunol. 2022;13:937583.
Patel PD, Alghareeb R, Hussain A, Maheshwari MV, Khalid N. The Association of Epstein-Barr virus with cancer. Cureus. 2022;14:e26314.
Jaeckel E, Manns M, von Herrath M. Viruses and diabetes. Ann N Y Acad Sci. 2002;958:7-25.
Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 1979;375:296-301.
Huang J, Lee SJ, Kang S, Choi MH, Im DS. 7 α,25-dihydroxycholesterol suppresses hepatocellular steatosis through GPR183/EBI2 in mouse and human hepatocytes. J Pharmacol Exp Ther. 2020;374:142-150.
Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K. Basic characteristics and representativeness of the German disease analyzer database. Int J Clin Pharmacol Ther. 2018;56:459-466.
Kap EJ, Konrad M, Kostev K. Clinical characteristics and sick leave associated with infectious mononucleosis in a real-world setting in Germany. Int J Clin Pract. 2021;75:e14690. doi:10.1111/IJCP.14690
Jördens MS, Luedde M, Roderburg C, et al. Pulmonary hypertension is associated with an increased incidence of NAFLD: a retrospective cohort study of 18,910 patients. J Intern Med. 2021;290:886-893.
Drebber U, Kasper HU, Krupacz J, et al. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol. 2006;44:879-885.
Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26:549-564.
Labenz C, Huber Y, Michel M, et al. Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany. Dig Dis Sci. 2020;65:2112-2119.
Labenz C, Kostev K, Alqahtani SA, Galle PR, Schattenberg JM. Impact of non-alcoholic fatty liver disease on metabolic comorbidities in type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes. 2022;130:172-177.